Type 2 Diabetes

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …

Imagine reducing your patients’ insulin injections from 365 a year to just 52. That’s the promise of once‑weekly insulin — a next-generation option designed to simplify treatment, enhance adherence, and improve patient outcomes. While this innovation is gaining traction, many healthcare providers still have questions about when and how to …

Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have revolutionized type 2 diabetes and obesity treatment—but could they also impact your brain? As headlines tout possible cognitive benefits, many patients and clinicians are asking: Can GLP‑1 drugs lower dementia risk? This article breaks down what we know so far, explains the science behind …

Early research suggests GLP‑1 drugs may reduce alcohol intake by dampening reward signaling and hedonic hunger, sparking interest among diabetes clinicians about the potential of GLP-1 alcohol use reduction. While findings so far are promising, understanding the nuances of the evidence is essential when talking with patients. This article explores …

GLP‑1 receptor agonists have transformed the way we manage type 2 diabetes and obesity—but could they also play a role in sleep apnea treatment? The intersection of GLP-1 sleep apnea benefits is gaining attention, with new evidence suggesting these therapies may offer more than just weight loss. With diabetes and …

The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes. These therapies, originally developed for glucose control, now show robust benefits in weight management. However, as use becomes more common in clinical practice, endocrinologists and primary care providers must balance glycemic outcomes, weight …

As the landscape of diabetes care evolves, one question continues to surface: are we focusing too much on glucose and not enough on the bigger cardiometabolic picture? In recent years, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have moved from glucose-focused agents to powerful tools in cardiovascular and metabolic risk reduction. …

Hospital discharge marks a critical juncture in the care of people with diabetes. It’s a period often riddled with risk—confusion about medications, fluctuating blood sugar levels, and a lack of follow-up can easily derail recovery. As clinicians, how can we improve post-discharge outcomes and reduce readmissions? This practical checklist offers …

Living with diabetes can take a serious toll on a person’s mental well-being. Depression, anxiety, and other psychiatric conditions often go hand-in-hand with chronic illnesses, and diabetes is no exception. Yet, despite the deep connection between mental health and diabetes, care for these conditions remains siloed. This article gives clinicians …

In a typical primary care or endocrinology visit, time is a precious resource. And while most clinicians understand the importance of diabetes nutrition counseling, it can be hard to know what to say—or how to say it—in just a few minutes. This article equips healthcare providers with brief, evidence-based scripts …